XML 149 R84.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue recognition - Narrative (Details)
 3 Months Ended 12 Months Ended
Dec. 31, 2022
USD ($)
Dec. 31, 2023
USD ($)
segment
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Oct. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Concentration Risk [Line Items]            
Number of reportable segments | segment   3        
Number of operating segments | segment   3        
Other assets $ 191,300,000 $ 194,300,000 $ 191,300,000      
Leases   5,700,000        
Revenue, remaining performance obligation, amount   379,500,000        
Contract with customer, asset, after allowance for credit loss, noncurrent 34,800,000 21,900,000 34,800,000      
Contract with customer, liability, current 26,400,000 27,200,000 26,400,000      
Provisions for expected credit losses   2,100,000 300,000 $ (100,000)    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01            
Concentration Risk [Line Items]            
Revenue, remaining performance obligation, amount   $ 372,300,000        
Revenue, remaining performance obligation, expected timing of satisfaction, period   24 months        
Leases            
Concentration Risk [Line Items]            
Leases   $ 5,700,000 4,900,000 305,200,000    
Lessor, operating lease, payment to be received, year one   800,000        
Lessor, operating lease, payment to be received, year two   900,000        
Lessor, operating lease, payment to be received, year three   900,000        
Lessor, operating lease, payment to be received, year four   900,000        
Lessor, operating lease, payment to be received, year five   900,000        
Lessor, operating lease, payment to be received, after year five   0        
Contracts and grants            
Concentration Risk [Line Items]            
Product sales   26,300,000 41,400,000 $ 134,200,000    
United States | Leases            
Concentration Risk [Line Items]            
Leases   $ 0 $ 0      
Non-USG            
Concentration Risk [Line Items]            
Lessee, operating lease, remaining lease term   5 years        
Revenue from Contract with Customer | Geographic Concentration Risk | United States            
Concentration Risk [Line Items]            
Concentration risk percentage   58.00% 79.00% 92.00%    
USG | Leases            
Concentration Risk [Line Items]            
Leases   $ 0 $ 0 $ 243,100,000    
USG | Contracts and grants            
Concentration Risk [Line Items]            
Product sales   $ 20,400,000 $ 37,200,000 $ 130,200,000    
USG | Revenue from Contract with Customer | Customer Concentration Risk            
Concentration Risk [Line Items]            
Concentration risk percentage   3800.00% 43.00% 51.00%    
Customer Two | Revenue from Contract with Customer | Customer Concentration Risk            
Concentration Risk [Line Items]            
Concentration risk percentage     10.00%      
Jansen Pharmaceuticals, Inc.            
Concentration Risk [Line Items]            
Increase in other assets $ 152,700,000          
Other assets   $ 158,800,000        
BARDA            
Concentration Risk [Line Items]            
Lessor, operating lease, payments to be received         $ 650,800,000 $ 628,200,000
Leases       $ 243,100,000    
BARDA | Contracts and grants            
Concentration Risk [Line Items]            
Product sales       $ 71,300,000    
BARDA | Reservation Of Manufacturing Capacity            
Concentration Risk [Line Items]            
Lessor, operating lease, payments to be received           542,700,000
BARDA | Accelerated Expansion Of Fill/Finish Capacity            
Concentration Risk [Line Items]            
Lessor, operating lease, payments to be received           $ 85,500,000